vs
Amphastar Pharmaceuticals, Inc.（AMPH）とデジタルオーシャン（DOCN）の財務データ比較。上の社名をクリックして会社を切り替えられます
デジタルオーシャンの直近四半期売上が大きい（$242.4M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.3倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 10.6%、差は2.8%）。デジタルオーシャンの前年同期比売上増加率が高い（18.3% vs -1.8%）。デジタルオーシャンの直近四半期フリーキャッシュフローが多い（$31.1M vs $24.6M）。過去8四半期でデジタルオーシャンの売上複合成長率が高い（14.5% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
デジタルオーシャンホールディングスは米国の多国籍テクノロジー企業かつクラウドサービスプロバイダーで、本社をコロラド州ブルームフィールドに置き、世界各地に15のデータセンターを保有している。開発者、スタートアップ、中小企業を対象にクラウドIaaSプラットフォームを提供している。
AMPH vs DOCN — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $242.4M |
| 純利益 | $24.4M | $25.7M |
| 粗利率 | 46.8% | 58.7% |
| 営業利益率 | 19.4% | 16.0% |
| 純利益率 | 13.3% | 10.6% |
| 売上前年比 | -1.8% | 18.3% |
| 純利益前年比 | -35.7% | 40.5% |
| EPS（希薄化後） | $0.51 | $0.23 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $242.4M | ||
| Q3 25 | $191.8M | $229.6M | ||
| Q2 25 | $174.4M | $218.7M | ||
| Q1 25 | $170.5M | $210.7M | ||
| Q4 24 | $186.5M | $204.9M | ||
| Q3 24 | $191.2M | $198.5M | ||
| Q2 24 | $182.4M | $192.5M | ||
| Q1 24 | $171.8M | $184.7M |
| Q4 25 | $24.4M | $25.7M | ||
| Q3 25 | $17.4M | $158.4M | ||
| Q2 25 | $31.0M | $37.0M | ||
| Q1 25 | $25.3M | $38.2M | ||
| Q4 24 | $38.0M | $18.3M | ||
| Q3 24 | $40.4M | $32.9M | ||
| Q2 24 | $37.9M | $19.1M | ||
| Q1 24 | $43.2M | $14.1M |
| Q4 25 | 46.8% | 58.7% | ||
| Q3 25 | 51.4% | 59.6% | ||
| Q2 25 | 49.6% | 59.9% | ||
| Q1 25 | 50.0% | 61.4% | ||
| Q4 24 | 46.5% | 57.1% | ||
| Q3 24 | 53.3% | 60.2% | ||
| Q2 24 | 52.2% | 61.0% | ||
| Q1 24 | 52.4% | 60.7% |
| Q4 25 | 19.4% | 16.0% | ||
| Q3 25 | 13.2% | 19.6% | ||
| Q2 25 | 24.2% | 16.3% | ||
| Q1 25 | 21.9% | 17.9% | ||
| Q4 24 | 24.2% | 15.9% | ||
| Q3 24 | 29.8% | 12.4% | ||
| Q2 24 | 30.3% | 11.6% | ||
| Q1 24 | 27.9% | 6.2% |
| Q4 25 | 13.3% | 10.6% | ||
| Q3 25 | 9.0% | 69.0% | ||
| Q2 25 | 17.8% | 16.9% | ||
| Q1 25 | 14.8% | 18.1% | ||
| Q4 24 | 20.4% | 8.9% | ||
| Q3 24 | 21.1% | 16.6% | ||
| Q2 24 | 20.8% | 9.9% | ||
| Q1 24 | 25.1% | 7.7% |
| Q4 25 | $0.51 | $0.23 | ||
| Q3 25 | $0.37 | $1.51 | ||
| Q2 25 | $0.64 | $0.39 | ||
| Q1 25 | $0.51 | $0.39 | ||
| Q4 24 | $0.74 | $0.21 | ||
| Q3 24 | $0.78 | $0.33 | ||
| Q2 24 | $0.73 | $0.20 | ||
| Q1 24 | $0.81 | $0.15 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $254.5M |
| 総負債低いほど良い | $608.7M | $1.3B |
| 株主資本純資産 | $788.8M | $-28.7M |
| 総資産 | $1.6B | $1.8B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $254.5M | ||
| Q3 25 | $276.2M | $236.6M | ||
| Q2 25 | $231.8M | $387.7M | ||
| Q1 25 | $236.9M | $360.4M | ||
| Q4 24 | $221.6M | $428.4M | ||
| Q3 24 | $250.5M | $439.9M | ||
| Q2 24 | $217.8M | $443.1M | ||
| Q1 24 | $289.6M | $419.1M |
| Q4 25 | $608.7M | $1.3B | ||
| Q3 25 | $608.6M | $1.3B | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | $1.5B | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $-28.7M | ||
| Q3 25 | $776.7M | $-69.6M | ||
| Q2 25 | $757.5M | $-175.2M | ||
| Q1 25 | $751.3M | $-210.7M | ||
| Q4 24 | $732.3M | $-203.0M | ||
| Q3 24 | $727.7M | $-211.7M | ||
| Q2 24 | $713.3M | $-253.8M | ||
| Q1 24 | $672.4M | $-286.1M |
| Q4 25 | $1.6B | $1.8B | ||
| Q3 25 | $1.7B | $1.7B | ||
| Q2 25 | $1.6B | $1.7B | ||
| Q1 25 | $1.6B | $1.6B | ||
| Q4 24 | $1.6B | $1.6B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.5B | $1.5B | ||
| Q1 24 | $1.6B | $1.5B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $57.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $31.1M |
| FCFマージンFCF / 売上 | 13.4% | 12.8% |
| 設備投資強度設備投資 / 売上 | 4.5% | 10.8% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 2.23× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $180.5M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $57.3M | ||
| Q3 25 | $52.6M | $95.8M | ||
| Q2 25 | $35.6M | $92.4M | ||
| Q1 25 | $35.1M | $64.1M | ||
| Q4 24 | $29.0M | $71.3M | ||
| Q3 24 | $60.0M | $73.4M | ||
| Q2 24 | $69.1M | $71.3M | ||
| Q1 24 | $55.3M | $66.7M |
| Q4 25 | $24.6M | $31.1M | ||
| Q3 25 | $47.2M | $88.0M | ||
| Q2 25 | $25.0M | $59.3M | ||
| Q1 25 | $24.4M | $2.1M | ||
| Q4 24 | $16.6M | $26.1M | ||
| Q3 24 | $46.2M | $16.0M | ||
| Q2 24 | $63.1M | $39.5M | ||
| Q1 24 | $46.5M | $23.0M |
| Q4 25 | 13.4% | 12.8% | ||
| Q3 25 | 24.6% | 38.3% | ||
| Q2 25 | 14.3% | 27.1% | ||
| Q1 25 | 14.3% | 1.0% | ||
| Q4 24 | 8.9% | 12.7% | ||
| Q3 24 | 24.1% | 8.1% | ||
| Q2 24 | 34.6% | 20.5% | ||
| Q1 24 | 27.1% | 12.5% |
| Q4 25 | 4.5% | 10.8% | ||
| Q3 25 | 2.8% | 3.4% | ||
| Q2 25 | 6.1% | 15.2% | ||
| Q1 25 | 6.3% | 29.4% | ||
| Q4 24 | 6.7% | 22.1% | ||
| Q3 24 | 7.2% | 28.9% | ||
| Q2 24 | 3.3% | 16.6% | ||
| Q1 24 | 5.1% | 23.6% |
| Q4 25 | 1.35× | 2.23× | ||
| Q3 25 | 3.03× | 0.60× | ||
| Q2 25 | 1.15× | 2.50× | ||
| Q1 25 | 1.39× | 1.68× | ||
| Q4 24 | 0.76× | 3.91× | ||
| Q3 24 | 1.48× | 2.23× | ||
| Q2 24 | 1.82× | 3.73× | ||
| Q1 24 | 1.28× | 4.72× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
DOCN
| Scalers | $84.3M | 35% |
| Scalers Plus | $69.9M | 29% |
| Builders | $64.1M | 26% |
| Learners Testers And Other | $24.1M | 10% |
